Table 2 Evaluation of efficacy of neoadjuvant Afatinib (n = 47)
From: Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Variables | No. of patient (%) |
|---|---|
Duration of NAT, cycle (range) | 2.7 (1-9) |
Surgery performed | 33 (70.2) |
Tumor response | |
PR | 33 (70.2) |
SD | 11 (23.4) |
PD | 2 (4.3) |
No Re-evaluation | 1 (2.1) |
ORR (%) | 70.2 |
DCR (%) | 93.6 |
MTD regression, % (range) | 36.0 (−28–78) |
cN downstaging | 37 (78.7) |
ypN downstaging # | 19 (57.6) |
ypTNM # | |
0/I | 14 (42.4) |
II | 5 (15.2) |
III | 14 (42.4) |
Type of surgery # | |
Thoracotomy | 16 (48.5) |
VATS | 17 (51.5) |
Surgical resection # | |
Lobectomy | 28 (84.8) |
Bi-Lobectomy | 5 (15.2) |
Resection # | |
R0 | 29 (87.9) |
R1 | 1 (3.0) |
R2 | 3 (9.1) |
Residual tumor cell, % (range) # | 57.3 (0-95) |
Residual tumor cell ≤ 60% # | 17 (51.5) |
Pathologic regression # | |
pCR | 1 (3.0) |
MPR | 3 (9.1) |
Non-MPR | 30 (90.9) |
Mean operation time (hour) | 2.4 |
Mean blood loss (mL) | 100 |
Mean hospital stay postoperatively, day (range) | 6.6 |
Mean chest drainage time, day (range) | 12.5 |
